Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Adrian Liston, professor of pathology at the University of Cambridge, UK, has published several illustrated children’s books on the topic of vaccination and has developed a computer game called ‘VirusFighter’. Here, he shares his thoughts on how to become an effective science communicator.
Sex hormones in male mice negatively regulate type 2 innate lymphoid cells in the skin, impairing the induction and activation of dendritic cells and thereby contributing to differences in immunity in males and females.
Sizun Jiang (while in the Garry Nolan lab) describes a method termed PANINI that allows simultaneous detection of nucleic acids at low copy numbers and protein markers in intact tissues, offering valuable insights into virus–immune system interactions and beyond.
This Review from Wellford and Moseman considers the unique immunology of the olfactory mucosa. The authors describe how stromal cells, innate immune cells and adaptive immune cells cooperate to defend the olfactory mucosa, protecting the host from potentially serious respiratory or neurotropic infections. They also discuss the relevance of olfactory mucosal immunology for the fields of vaccination and neurodegeneration.
In this Review, Butterfield and Najjar discuss the rationale for combination strategies in cancer, including combinations of different immunotherapies and combinations of immunotherapies with other types of therapies. Moreover, they examine the evolution of biomarker approaches to guide such therapies.
This Review provides an updated assessment of the expanding family of T cell-activating bacterial superantigens, emphasizing potential roles of these toxins in various disease states as well as their contribution to the evolution of the bacterial pathogens Staphylococcus aureus and Streptococcus pyogenes.
The first immune-targeted drug for type 1 diabetes (T1D), teplizumab, received regulatory approval by the US FDA in 2022. In this Review, Herold, Walker and colleagues examine the immune mechanisms that underpin T1D and provide an overview of immune-targeted strategies for T1D that are currently in development.
